Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Repros Therapeutics Company Profile (NASDAQ:RPRX)

Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $32.50 (316.67% upside)

Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
DateFirmActionRatingPrice TargetDetailsShare
5/1/2015ZacksReiterated RatingHold -> HoldViewTweet This Rating  Share This Rating on StockTwits
4/8/2015Brean CapitalReiterated RatingBuy$41.00ViewTweet This Rating  Share This Rating on StockTwits
3/16/2015Brean CapitalReiterated RatingBuy$41.00ViewTweet This Rating  Share This Rating on StockTwits
9/3/2014Piper JaffrayDowngradeOverweight -> Neutral$33.00 -> $24.00ViewTweet This Rating  Share This Rating on StockTwits
8/29/2014Ascendiant Capital MarketsReiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
11/26/2013Piper JaffrayInitiated CoverageOverweight$26.00ViewTweet This Rating  Share This Rating on StockTwits
10/23/2013Ascendiant Capital MarketsDowngradeStrong-Buy -> Buy$25.00ViewTweet This Rating  Share This Rating on StockTwits
9/19/2013Ladenburg ThalmannBoost Price TargetBuy$25.00 -> $35.00ViewTweet This Rating  Share This Rating on StockTwits
9/18/2013Bank of AmericaReiterated RatingBuy$25.00 -> $35.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2013Brean CapitalReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
7/29/2013Brean CapitalInitiated CoverageBuy$32.00ViewTweet This Rating  Share This Rating on StockTwits
7/2/2013Bank of AmericaInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
6/7/2013Lazard Capital MarketsBoost Price TargetBuy$29.00 -> $31.00ViewTweet This Rating  Share This Rating on StockTwits
5/14/2013Ascendiant Capital MarketsBoost Price TargetStrong-Buy$19.00 -> $23.00ViewTweet This Rating  Share This Rating on StockTwits
5/9/2013Roth CapitalBoost Price TargetBuy$25.00 -> $31.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 5/4/2013 forward)